share_log

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9

Benzinga ·  Aug 8, 2023 04:28

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $11 to $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment